Literature DB >> 7896852

Involvement of early growth response factor Egr-1 in apolipoprotein AI gene transcription.

E J Kilbourne1, R Widom, D C Harnish, S Malik, S K Karathanasis.   

Abstract

Liver-specific expression of the apolipoprotein AI (apoAI) gene is mediated by transcription factors bound to three sites (A, B, and C) in the apoAI enhancer. Sites A and C bind various members of the nuclear receptor superfamily, including the orphan nuclear receptor apolipoprotein regulatory protein-1 (ARP-1); site B binds the liver-enriched factor hepatic nuclear factor-3. The immediate early growth response factor (Egr-1), which is transiently expressed in various pathophysiologic states of the liver, activates the apoAI enhancer and overcomes ARP-1-mediated repression of the enhancer in hepatoblastoma HepG2 cells. Deletion mapping analysis revealed two Egr-1 binding sites, E1 and E2, flanking site A. Erg-1 bound efficiently to both E1 and E2. Sp1 in HepG2 nuclear extracts bound to E2 but not E1. In HepG2 cells, E1 functioned as an Egr-1 response element, whereas E2 had high basal activity and was not further induced by Egr-1. Mutations that prevent Egr-1 binding to the apoAI enhancer abolished its responsiveness to Erg-1, while they had only minor effects on its constitutive activity. These mutations also diminished the ability of Egr-1 to overcome ARP-1-mediated repression. Elimination of transcription factor binding to sites A, B, or C reduced enhancer activity without affecting Egr-1-dependent activation. We argue that Egr-1 is recruited to the apoAI enhancer complex under unusual circumstances, such as those prevailing during liver regeneration, to maintain apoAI transcription levels by overriding prior transcriptional controls.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7896852     DOI: 10.1074/jbc.270.12.7004

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Pathways of Egr-1-mediated gene transcription in vascular biology.

Authors:  E S Silverman; T Collins
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

2.  E1A represses apolipoprotein AI enhancer activity in liver cells through a pRb- and CBP-independent pathway.

Authors:  E J Kilbourne; M J Evans; S K Karathanasis
Journal:  Nucleic Acids Res       Date:  1998-04-01       Impact factor: 16.971

3.  Intestinal transcription and synthesis of apolipoprotein AI is regulated by five natural polymorphisms upstream of the apolipoprotein CIII gene.

Authors:  S Naganawa; H N Ginsberg; R M Glickman; G S Ginsburg
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

4.  High-level expression of Egr-1 and Egr-1-inducible genes in mouse and human atherosclerosis.

Authors:  T A McCaffrey; C Fu; B Du; S Eksinar; K C Kent; H Bush; K Kreiger; T Rosengart; M I Cybulsky; E S Silverman; T Collins
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

5.  The full induction of human apoprotein A-I gene expression by the experimental nephrotic syndrome in transgenic mice depends on cis-acting elements in the proximal 256 base-pair promoter region and the trans-acting factor early growth response factor 1.

Authors:  M Zaiou; N Azrolan; T Hayek; H Wang; L Wu; M Haghpassand; B Cizman; M P Madaio; J Milbrandt; J B Marsh; J L Breslow; E A Fisher
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

Review 6.  High density lipoprotein, apolipoprotein A-I, and coronary artery disease.

Authors:  R A Srivastava; N Srivastava
Journal:  Mol Cell Biochem       Date:  2000-06       Impact factor: 3.396

7.  Vascular smooth muscle cells express the transcriptional corepressor NAB2 in response to injury.

Authors:  E S Silverman; L M Khachigian; F S Santiago; A J Williams; V Lindner; T Collins
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

8.  Role of early growth response 1 in liver metabolism and liver cancer.

Authors:  Nancy Magee; Yuxia Zhang
Journal:  Hepatoma Res       Date:  2017-11-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.